Understand the source comparison
AOD-9604 Alternative to Wegovy: Research Peptide Comparison
Regulatory Status Research compound only. No FDA approval for human use FDA-approved for chronic weight management in adults with BMI ≥30 or ≥27 with comorbidities Prepared by 503B facilities; not FDA-approved as finished product but contains FDA-approved acti
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Regulatory Status
- Research compound only. No FDA approval for human use
- FDA-approved for chronic weight management in adults with BMI ≥30 or ≥27 with comorbidities
- Prepared by 503B facilities; not FDA-approved as finished product but contains FDA-approved active molecule
- Wegovy and compounded semaglutide share the same active mechanism; AOD-9604 is investigational
- Primary Mechanism
- Synthetic HGH fragment (176–191) targeting adipocyte lipolysis without GH receptor binding
- GLP-1 receptor agonist. Suppresses appetite, slows gastric emptying, extends satiety signaling
- Identical to Wegovy. Same GLP-1 receptor agonism
- GLP-1 agonists have consistent human efficacy data; AOD-9604 mechanism not validated in humans
- Clinical Evidence
- 2008 RCT (n=536) showed no significant weight loss vs placebo at 12 weeks
- STEP trial program (5 Phase 3 studies, n=4,500+) showed 12–15% mean body weight reduction at 68 weeks
- Same pharmacological profile as Wegovy; clinical outcomes expected to mirror branded trials
- Wegovy's evidence base is robust; AOD-9604's human data is limited and inconclusive
- Dosing Protocol
- No standardised therapeutic dosing. Research doses range 1–10mg/day subcutaneous
- 2.4mg once weekly subcutaneous, titrated over 16–20 weeks
- Typically mirrors Wegovy dosing schedule but varies by prescriber
- Wegovy has established titration schedule; AOD-9604 lacks formal dosing guidance
- Common Side Effects
- Minimal GI effects reported in trials; injection site reactions noted
- Nausea (44%), diarrhoea (30%), vomiting (24%) during titration; typically resolve in 4–8 weeks
- Same GI side effect profile as Wegovy
- GLP-1 agonists carry predictable side effects; AOD-9604 has limited safety data
- Cost (Approximate)
- $80–$150/month (research supplier pricing)
- $1,300–$1,600/month without insurance
- $250–$500/month from compounding pharmacy
- Compounded semaglutide offers 60–85% cost reduction vs Wegovy; AOD-9604 pricing reflects research-only status